Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
UCB SA (EBR: UCB) bets $1.15 bn on Neurona Therapeutics to push epilepsy treatment beyond symptom control
Read More Pharma Industry News Biocon faces regulatory heat as USFDA flags critical issues at its Bengaluru facility In a significant development that has sent shockwaves through the biotechnology industry, Biocon Ltd. has come under fire… byPallavi MadhirajuSeptember 30, 2024